The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptorLivia Stanger, Michael Holinstat, Adriana Yamaguchi et al.|Blood|2023Cited by 18
Comparison of the Anti-Platelet and Anti-Thrombotic Effects of the Dual SGLT1/2 Inhibitor Sotagliflozin to the Relatively Selective SGLT2 Inhibitor EmpagliflozinLivia Stanger, Michael Holinstat, Pooja Yalavarthi et al.|Blood|2024Cited by 5
HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of BleedingLivia Stanger, Björn Dahlöf, Michael Holinstat et al.|Blood|2023Cited by 1
Abstract 4134384: Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Transporters 1 and 2, Elicits Cardioprotective Effects Through Attenuation of Platelet Activation and ThrombosisLivia Stanger, Michael Holinstat, Andrew Rickenberg et al.|Circulation|2024Cited by 1
Abstract 4137045: Sustained Anti-Thrombotic Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic PotentialLivia Stanger, Michael Holinstat, Mariane Flores et al.|Circulation|2024Cited by 0